Navigation Links
NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
Date:6/3/2008

SAN MATEO, Calif., June 3 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration for the clinical development of NGX-1998, the Company's product candidate utilizing a high-concentration liquid formulation of capsaicin. The Company further announced that the IND is now effective and that it may commence clinical studies under this IND.

Anthony DiTonno, President and CEO, commented, "The opening of the IND for NGX-1998 is an important milestone for NeurogesX as it allows us to commence the clinical development of the high-concentration liquid capsaicin formulation. NGX-1998 contains the same active ingredient as our lead product candidate, NGX-4010, but its proprietary liquid formulation is designed to enable rapid delivery of capsaicin into the skin. In doing so, we believe that NGX-1998 offers the potential for short treatment times and the potential for expanding the addressable market of our capsaicin based product candidate pipeline."

NGX-1998 was previously studied in two Phase I studies in healthy volunteers conducted under an exploratory IND. With the new IND in place, NeurogesX intends to initiate a Phase I clinical trial in 2008 to evaluate potential controls for studies in peripheral neuropathic pain.

About NeurogesX, Inc.

NeurogesX (NASDAQ: NGSX) is a biopharmaceu
'/>"/>

SOURCE NeurogesX
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... This market report summarizes the ... carried out in May 2013. The full report ... the responses for each question, its segmentation and ... highlights some interesting differences, particularly between Pharma, Biotech ... were developed to estimate the in house and ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 The Oklahoma ... And following its ravage, the mayor of Moore, one of ... new houses, said a report from cnn.com. Reaching out to ... victims complimentary Molderizer and Safe Shield to counter the looming ... report published on May 22, 2013, caused 24 deaths, My ...
(Date:5/24/2013)... WI (PRWEB) May 24, 2013 ... the discovery and development of calcium-binding proteins to ... of safety assessment study of apoaequorin ... international journal published for the British Industrial Biological ... study was to investigate potential adverse effects, if ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
... into an old idea, MIT Institute Professor Mildred ... for controlling temperatures that could lead to substantial ... photovoltaic cells and electronic devices. , Novel ... consumer product: a simple, efficient way of cooling ...
... EXEL ) announced today that that it will hold its,Third Annual ... /,7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT ... be accessed in the Event Calendar,page under Investors at http://www.exelixis.com ... 9:00 p.m. PT / 12:00,a.m. ET on January 4, 2008. Access ...
... Nov. 20 ,Exelixis, Inc. (Nasdaq: EXEL ) ... with Taconic Farms, Inc. (Hudson, NY) pursuant to ... subsidiary Artemis Pharmaceuticals GmbH,for approximately $20 million, subject ... the research, development and commercialization of,genetically engineered mouse ...
Cached Biology Technology:MIT: Thermoelectric materials are 1 key to energy savings 2MIT: Thermoelectric materials are 1 key to energy savings 3Exelixis Sells 80% Stake in Artemis to Taconic 2Exelixis Sells 80% Stake in Artemis to Taconic 3Exelixis Sells 80% Stake in Artemis to Taconic 4
(Date:5/23/2013)... age when microbial pathogens are growing increasingly resistant to ... team of Wisconsin scientists has synthesized a potent new ... cause staph infections. , Writing online in the ... led by University of Wisconsin-Madison chemistry Professor Helen Blackwell ... behavior of Staphylococcus aureus , a bacterium at ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2Detecting mirror molecules 2Detecting mirror molecules 3
... when superheroes band together the bad guys fall harder. The ... of its parts. The same holds true, researchers have ... ) and snapping shrimp ( Alepheus lottini ) in the ... hungry seastars. In these frequent conflicts "one-plus-one doesn,t always equal ...
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
... Institutes of Health has awarded The Scripps Research Institute $2 ... development and maintenance of B-cell lymphoma, a type of cancer ... cells into cancers. The disease affects immune cells known as ... John Cleveland, PhD, chair of the Department of Cancer ...
Cached Biology News:Preventing home invasions means fighting side-by-side for coral-dwelling crabs and shrimp 2Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2Scientists win $2 million to study new pathway in development and maintenance of lymphoma 2
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Quartz-Halogen, 100 W, High Intensity...
... the translation boosting Cap 1 structure. mScript™ ... 40% to 80% capped using co-transcriptional systems) ... mScript™ also features the Cap 1 structure, ... to 50% more efficient in in vivo ...
...
Biology Products: